Targeting ACYP1-mediated glycolysis reverses lenvatinib resistance and restricts hepatocellular carcinoma progression
Drug Resistance Updates · 2023-07 · 69 · 100976
DOI: 10.1016/j.drup.2023.100976 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Resistance Updates, 2023-07. Verfasst von Shuai Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary Oncology, Liver Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Cente…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 103-mal zitiert (Crossref) und nennt 46 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatobiliary Oncology, Liver Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin…
- Department of Blood Transfusion, Tianjin Medical University General Hospital, Tianjin, PR China.
- Department of Clinical Laboratory, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Cen…
- Department of Oncology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Shandong L…
- Department of Pain Relief, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University, Tianjin 300…
Zitieren
APA
Wang, S., Zhou, L., Ji, N., Sun, C., Sun, L., Sun, J., Du, Y., Zhang, N., Li, Y., Liu, W., & Lu, W. (2023). Targeting ACYP1-mediated glycolysis reverses lenvatinib resistance and restricts hepatocellular carcinoma progression. Drug Resistance Updates, 69, 100976. https://doi.org/10.1016/j.drup.2023.100976
Vancouver
Wang S, Zhou L, Ji N, Sun C, Sun L, Sun J, et al. Targeting ACYP1-mediated glycolysis reverses lenvatinib resistance and restricts hepatocellular carcinoma progression. Drug Resistance Updates. 2023;69:100976. doi:10.1016/j.drup.2023.100976
BibTeX
@article{Wang2023,
author = {Wang, Shuai and Zhou, Lingyi and Ji, Ning and Sun, Chengtao and Sun, Linlin and Sun, Jiao and Du, Yawei and Zhang, Ningning and Li, Yueguo and Liu, Weishuai and Lu, Wei},
title = {Targeting ACYP1-mediated glycolysis reverses lenvatinib resistance and restricts hepatocellular carcinoma progression},
journal = {Drug Resistance Updates},
year = {2023},
volume = {69},
pages = {100976},
doi = {10.1016/j.drup.2023.100976}
}
EUVIMED